Non-valvular atrial fibrillation: Potential clinical implications of the heterogeneous definitions used in trials on new oral anticoagulants

Journal of Cardiovascular Medicine

Volumn 16, Issue 7, 2015, Pages 491-496

  Boriani, Giuseppe ^a   Cimaglia, Paolo ^a   Fantecchi, Elisa ^a   Mantovani, Valentina ^a   Ziacchi, Matteo ^a   Valzania, Cinzia ^a   Martignani, Cristian ^a   Biffi, Mauro ^a   Diemberger, Igor ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Anticoagulants; Atrial fibrillation; Trials; Valvular heart disease; Valvular prosthesis

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; WARFARIN;

AGED; ARTICLE; ATRIAL FIBRILLATION; CHADS2 SCORE; CLINICAL PRACTICE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; NON VALVULAR ATRIAL FIBRILLATION; OBSERVATIONAL STUDY; PERMANENT ATRIAL FIBRILLATION; VALVULAR HEART DISEASE; COMPLICATION; MIDDLE AGED; NOMENCLATURE; ORAL DRUG ADMINISTRATION; PATIENT SELECTION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HEART VALVE DISEASES; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TERMINOLOGY AS TOPIC;

EID: 84942982049     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0000000000000236     Document Type: Article

References (31)

1. Boriani G, Diemberger I, Martignani C, et al. The epidemiological burden of atrial fibrillation: a challenge for clinicians and healthcare systems. Eur Heart J 2006;27:893-894.
2. Zoni-Berisso M, Filippi A, Landolina M, et al. Frequency, patient characteristics, treatment strategies, and resource usage of atrial fibrillation (from the Italian Survey of Atrial Fibrillation Management [ISAF] study). Am J Cardiol 2013;111:705-711.
3. Boriani G, Diemberger I. Globalization of the epidemiologic, clinical, and financial burden of atrial fibrillation. Chest 2012;142:1368-1370.
4. Kirchhof P, Breithardt G, Aliot E, et al. Personalized management of atrial fibrillation: proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. Europace 2013;15:1540-1556.
5. Boriani G, Diemberger I, Ziacchi M, et al. AF burden is important: fact or fiction? Int J Clin Pract 2014;68:444-452.
6. Gostoli S, Rafanelli C, Offidani E, et al. Well being, ill-being and symptoms of atrial fibrillation. J Cardiovasc Med (Hagerstown) 2014;15:260-262.
7. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESCGuidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-2747.
8. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-2429.
9. Lip GY. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? Eur Heart J 2013;34:1041-1049.
10. De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis: task force on anticoagulants in heart disease. Thromb Haemost 2013;110:1087-1107.
11. Pereira de Sousa L, Burba I, Ruperto C, et al. Vitamin K antagonists in patients with nonvalvular atrial fibrillation: appropriateness and quality of treatment in an Italian cohort. J Cardiovasc Med (Hagerstown) 2013;14:534-540.
12. Dentali F, Riva N, Crowther M, et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012;126:2381-2391.
13. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-962.
14. Becattini C, Vedovati MC, Agnelli G. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature. Thromb Res 2012;129:392-400.
15. Kasmeridis C, Apostolakis S, Ehlers L, et al. Cost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel oral anticoagulants. Pharmacoeconomics 2013;31:971-980.
16. Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009;157:805-810.
17. Randomized evaluation of long term anticoagulant therapy (RE-LY) with dabigatran etexilate. ClinicalTrials.gov Identifier: NCT00262600. https://clinicaltrials.gov/ct2/show/NCT00262600?term=re-ly&rank=2. [Accessed 7 May 2014]
18. ROCKET AF Study Investigators. Rivaroxaban: once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET-AF study. Am Heart J 2010;159:340e1-347e1.
19. Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010;159:331-339.
20. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010;160:635-641.
21. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:e269-e367.
22. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014; [Epub ahead of print] DOI: 10.1161/CIR.0000000000000041.
23. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206-1214.
24. You JJ, Singer DE, Howard P, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis. 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl);e531S-75S.
25. Molteni M, Polo Friz H, Primitz L, et al. The definition of valvular and nonvalvular atrial fibrillation: results of a physicians' survey. Europace 2014;16:1720-1725.
26. Berisso MZ, Fabbri G, Gonzini L, et al. Antiarrhythmic strategies in patients with atrial fibrillation managed by cardiologists and internists: Antithrombotic Agents in Atrial Fibrillation (ATA-AF) survey. J Cardiovasc Med (Hagerstown) 2014;15:626-635.
27. Mohammed I, Mohmand-Borkowski A, Burke JF, Kowey PR. Stroke prevention in atrial fibrillation. J Cardiovasc Med (Hagerstown) 2012;13:73-85.
28. Friberg L, Engdahl J, Frykman V, et al. Population screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP). Europace 2013;15:135-140.
29. Boriani G, Glotzer TV, Santini M, et al. Device-detected atrial fibrillation and risk for stroke: an analysis of >10, 000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J 2014;35:508-516.
30. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 2014;6:213-220.
31. Boriani G, Valzania C, Biffi M, et al. Asymptomatic lone atrial fibrillation: how can we detect the arrhythmia? Curr Pharm Des 2014;21:659-666.